Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Wilfredo Villarrubia

Physician Assistant, Medical West Columbia, SC Physician Assistant

NPI 1568992030 CMS profile 10749472

146 E Hospital Dr Ste 550, West Columbia, SC 29169

Open in the dashboard

General payments

$4,705

126 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Wilfredo Villarrubia of West Columbia, SC is reported in the CMS Open Payments database as having received $4,705 across 126 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $880 41
2024 General $1,203 39
2023 General $1,361 28
2022 General $1,261 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wilfredo Villarrubia
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Wilfredo Villarrubia were reported at $880. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Wilfredo Villarrubia Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $0 $156 $41–$563 $132
2022 $1,261 $185 $55–$649 $149
2023 $1,361 $199 $58–$717 $160
2024 $1,203 $206 $62–$740 $164
2025 $880 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. GlaxoSmithKline, LLC. $1,112 39 payments
  2. AstraZeneca Pharmaceuticals LP $1,075 15 payments
  3. Amgen Inc. $801 21 payments
  4. Janssen Biotech, Inc. $316 4 payments
  5. Janssen Scientific Affairs, LLC $268 2 payments
  6. AbbVie, Inc. $244 9 payments
  7. UCB, Inc. $153 7 payments
  8. Aurinia Pharma U.S., Inc. $141 3 payments
  9. Grifols USA, LLC $92 2 payments
  10. Fresenius Kabi USA, LLC $80 3 payments
  11. Other $424 21 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $4,502 123 payments
  2. Education $203 3 payments
Products named General payments · program years 2022–2025
  1. TEZSPIRE Respiratory $769 7 payments
  2. NUCALA $653 22 payments
  3. TREMFYA $584 6 payments
  4. BENLYSTA $450 16 payments
  5. TEZSPIRE Inflammation $379 6 payments
  6. SAPHNELO $306 8 payments
  7. TAVNEOS $186 6 payments
  8. LUPKYNIS $141 3 payments
  9. Bimzelx $132 6 payments
  10. SKYRIZI $126 4 payments
  11. Other $1,031 43 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 79 drugs

Part D claims

8,438

Median for Physician Assistant: 241

Drug cost

$18,157,476

Median for Physician Assistant: $4,110

Branded share of claims

50.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 640 $5,683,211
Enbrel Sureclick Etanercept Brand 384 $3,255,784
Rinvoq Upadacitinib Brand 123 $946,664
Orencia Clickject Abatacept Brand 137 $860,459
Nucala Mepolizumab Brand 117 $716,374
Xolair Omalizumab Brand 213 $650,558
Enbrel Mini Etanercept Brand 78 $650,064
Xeljanz Tofacitinib Citrate Brand 93 $625,382
Cosentyx Sensoready (2 Pens) Secukinumab Brand 67 $455,217
Dupixent Pen Dupilumab Brand 110 $455,027

The 10 drugs with the highest cost, of 79 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$15,472

Medicare's payments for the services billed

Medicare patients

163

Average age 70

Services billed

564

116 women, 47 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Diabetes 31%
Ischemic heart disease 29%
Osteoporosis 25%
Depression 18%
Chronic kidney disease 16%
Heart failure 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUCALA
  • GlaxoSmithKline, LLC. $263
$263 117 —
TAVNEOS
  • Amgen Inc. $151
$151 — —
BENLYSTA
  • GlaxoSmithKline, LLC. $140
$140 55 —
LUPKYNIS
  • Aurinia Pharma U.S., Inc. $97
$97 — —
TREMFYA
  • Janssen Biotech, Inc. $56
$56 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

126 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record